Predictors of long-term drug survival for infliximab in psoriasis.
BACKGROUND
Limited information is available regarding factors associated with long-term drug survival of infliximab for psoriasis in real life.


OBJECTIVE
The main aim pf this study was to identify predictors of long-term (>12 months) drug survival among patients treated with infliximab for psoriasis in a real-world clinical setting.


METHODS
Retrospectively collected data, relating to disease, patient characteristics and treatment procedures, in a multicentre observational cohort of patients with moderate-to-severe plaque psoriasis treated with infliximab at eight university hospitals, 120 of whom maintained a response to infliximab for more than 12 months, were compared with prospectively collected data in the same centres from 54 patients who experienced secondary loss of response within a 12-month period.


RESULTS
Mean duration of drug survival of infliximab in patients with long-term drug survival was 41.12 months ± 20.64 SD vs. 8.5 months ± 2.43 SD in patients with a secondary loss of response. Multivariate analysis identified greater disease severity at treatment onset (PASI score >12) (OR = 5.18, 95% CI: 1.60-16.77, P = 0.006), high levels of initial psoriasis clearance (PASI-90 reduction or equivalent) (OR = 18.50, 95% CI: 4.56-74.45, P = 0.0001) and combination with methotrexate (OR = 13.15, 95% CI: 1.46-118.79, P = 0.022) as independent predictors of long-term drug survival and sustained efficacy of infliximab.


CONCLUSIONS
Positive predictors for long-term drug survival of infliximab in real life were identified. Their impact on treatment management should be addressed in further prospective trials.
Department of Dermatology, Hôpital Timone, Assistance Publique des Hôpitaux de Marseille, UMR 911, INSERM CRO2, "Centre de recherche en oncologie biologique et onco phamacologie", Aix-Marseille University, Marseille, France.
Q
Q
Magis
Department of Dermatology Hôpital Edouard Herriot, University Claude Bernard Lyon-1, University of Lyon, Lyon, France.
D
D
Jullien
Department of Dermatology, Hôpital Timone, Assistance Publique des Hôpitaux de Marseille, UMR 911, INSERM CRO2, "Centre de recherche en oncologie biologique et onco phamacologie", Aix-Marseille University, Marseille, France.
C
C
Gaudy-Marqueste
Clinical Research Platform, Assistance Publique des Hôpitaux de Marseille, EA 3279 "Qualité de vie et maladies chroniques", Aix-Marseille University, Marseille, France.
K
K
Baumstark
Department of Dermatology, AP-HP Hôpital Saint Louis, University Paris Diderot, Sorbonne Paris Cité, Paris, France.
M
M
Viguier
Department of Dermatology, AP-HP Hôpital Saint Louis, University Paris Diderot, Sorbonne Paris Cité, Paris, France.
H
H
Bachelez
Department of Dermatology, AP-HP Hôpital Saint Louis, University Paris Diderot, Sorbonne Paris Cité, Paris, France.
F
F
Guibal
Regional University Hospital, Lille, France.
E
E
Delaporte
Regional University Hospital, Lille, France.
E
E
Karimova
Hôpital L'Archet, Nice, France.
H
H
Montaudié
Hôpital d'instruction des armées St Anne, Toulon, France.
T
T
Boye
Regional University Hospital Hôpital Jean Minjoz, Besançon, France.
F
F
Aubin
Department of Dermatology, Hôpital Saint-André, University of Bordeaux, Bordeaux, France.
M
M
Beylot-Barry
Department of Dermatology, Hôpital Timone, Assistance Publique des Hôpitaux de Marseille, UMR 911, INSERM CRO2, "Centre de recherche en oncologie biologique et onco phamacologie", Aix-Marseille University, Marseille, France.
M-A
MA
Richard
D000328:Adult; D000368:Aged; D015331:Cohort Studies; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D005602:France; D006801:Humans; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*
D003879:Dermatologic Agents; D000069285:Infliximab